• Prescribing Information
  • Patient Information
  • Patient Site
    • HomeEfficacySafety DataReal-World PatientsDosingSavings & Support
    Menu
    Phase III Study Primary Endpoint*
    Phase III Study Secondary Endpoints*
    Phase III Study: Other Endpoints*
    Infant Study: Exploratory Endpoint**

    *Phase III pivotal studies and open-label safety extension study investigated in patients 2 years and older

    **Infant study investigated patients aged 3 to <24 months

    *Phase III pivotal studies and open-label safety extension study investigated in patients 2 years and older

    **Infant study investigated patients aged 3 to <24 months

    EUCRISA Efficacy

    Steroid-Free EUCRISA has proven efficacy in patients ≥ 2 years

    In an open-label, single-arm, 28 day safety trial of 137 infant patients aged 3 to <24 months in which efficacy was an exploratory objective

    Treatable % body surface area (BSA)

    Decrease in mean treatable %BSA affected with atopic dermatitis from 28.1% at baseline to 12.4% at Day 29.

    Patients were excluded from the PK cohort if they had lesions below their wrists and ankles or 2 cm around their mouth. 
    Calculation of treatable %BSA excluded the scalp.

    Eczema Area and Severity Index (EASI) - Mean % Change From Baseline

    EASI is an objective grading tool used to measure the severity and extent of AD

    EASI=Eczema Area and Severity Index; SE=Standard error

    Eczema Area and Severity index (EASI)

    Mean change in total Patient-Oriented Eczema Measure (POEM) score from baseline to day 29*

    EASI=Eczema Area and Severity Index; SE=Standard error

    Mean change in POEM subscale scores* from baseline to day 29

    *Data are sub-scale scores of POEM and are not specific measures for pruritus, sleep, or skin evaluation

    Patient-Oriented Eczema Measure (POEM)

    EUCRISA was studied in patients aged 3 to <24 months
    See Infant Safety Study Design
    References
    1. ​​​​​​​Schlessinger J, Shepard JS, Gower R, et al. Safety, effectiveness, and pharmacokinetics of crisaborole in infants aged 3 to <24 months with mild-to-moderate atopic dermatitis: a phase IV open-label study (CrisADe CARE 1). Am J Clin Dermatol. 2020. 21:275-284.
    If babies could talk, what would they tell you?

    Hear JP with mild-to-moderate AD explain what EUCRISA means to him and other babies like him

    Not an actual patient

    Watch JP's story

    Pivotal Trial Primary Efficacy Endpoint

    Find out more about the proportion of patients who achieved clear or almost clear at day 29 in the primary endpoint

    Learn More

    ** This is an optional area where footnotes can live.

    3 to <24 Month Study Data

    Learn more about 28-day, open-label, single-arm, safety study in 3 to <24 month old patients1

    See data

    ** This is an optional area where footnotes can live.
    Learn how the first and only nonsteroidal topical PDE4 inhibitor works within the skin1

    The specific mechanism(s) of action of crisaborole in atopic dermatitis is not well defined. PDE4=phosphodiesterase 4

    Learn more

    Copay Cards

    *Eligible patients pay as little as $10​​​​​​

    Terms and Conditions apply​​​​​​

    ​​​​* Patients enrolled in state or federally funded prescription insurance programs are not eligible to use this card. Savings up to $970 per tube. Annual savings up to $3,880. This card will be accepted only at participating pharmacies. This card is not health insurance.

    Download Copay cards

    ** This is an optional area where footnotes can live.

    Savings & Support Program

    A savings and support program for your patients to help them with their access to EUCRISA

    See resources

    ** This is an optional area where footnotes can live.

    Order Samples

    Register or sign in to check availability and request samples.

    Order now

    ** This is an optional area where footnotes can live.

    Contraindications

    EUCRISA is contraindicated in patients with known hypersensitivity to crisaborole or any component of the formulation.

    Warnings and Precautions

    Hypersensitivity reactions, including contact urticaria, have occurred in patients treated with EUCRISA and should be suspected in the event of severe pruritus, swelling, and erythema at the application site or at a distant site. Discontinue EUCRISA immediately and initiate appropriate therapy if signs and symptoms of hypersensitivity occur.

    Adverse Reactions

    The most common treatment-related adverse reaction occurring in clinical trials was application site pain, such as burning or stinging.

    Please see Full Prescribing Information and Patient Information

    EUCRISA is indicated for topical treatment of mild-to-moderate atopic dermatitis in adult and pediatric patients 3 months of age and older.

    INDICATION

    EUCRISA (crisaborole) is indicated for topical treatment of mild‑to‑moderate atopic dermatitis in adult and pediatric patients 3 months of age and older.

    EUCRISA is for topical use only and is not for ophthalmic, oral, or intravaginal use. For more information, please view the full prescribing information here.